In a regulatory disclosure, Medicamen Biotech has informed that it has entered into a long-term Manufacturing & Supply Agreement with a prominent pharmaceutical distributor and marketing entity operating in the United States and Europe.
- Neither the name of the customer nor the financial details of the contract are disclosed.
- The company, however, has informed that
- collaboration is expected to last for ten years;
- the agreement is strictly a manufacturing and supply arrangement with no share exchange involved; and
- 25% of the agreement’s total consideration has been received upon signing
In November 2024, the Company had informed that it’s Sterile injectable Facility Received has received USFDA Approval; opening doors to the regulated markets globally.
The current announcement seems to be further to that approval.